Hörnsten P, Keisu M, Wiholm B E
Department of Hematology, University Hospital, Umeå, Sweden.
Arch Dermatol. 1990 Jul;126(7):919-22. doi: 10.1001/archderm.1990.01670310081011.
During the 17-year period 1972 through 1988, a total of seven cases of agranulocytosis associated with the use of dapsone for the treatment of dermatitis herpetiformis were reported in Sweden. The median age of the patients involved was 61 years; three of them were male. The median duration of dapsone treatment was 7 weeks and the daily prescribed dose was 100 mg. Based on sales and prescription data, the crude relative risk of agranulocytosis during dapsone treatment of dermatitis herpetiformis was 50, and the total risk was one case per 3000 patient years of exposure to dapsone. In relation to the number of new cases of dermatitis herpetiformis, agranulocytosis was estimated to develop in 1 of 240 to 425 patients receiving dapsone therapy. Patients should be instructed to seek medical care immediately in case of fever.
在1972年至1988年的17年期间，瑞典共报告了7例与使用氨苯砜治疗疱疹样皮炎相关的粒细胞缺乏症病例。所涉患者的中位年龄为61岁；其中3例为男性。氨苯砜治疗的中位持续时间为7周，每日规定剂量为100毫克。根据销售和处方数据，氨苯砜治疗疱疹样皮炎期间粒细胞缺乏症的粗相对风险为50，总风险为每3000患者年接触氨苯砜有1例。相对于疱疹样皮炎的新病例数，估计接受氨苯砜治疗的240至425名患者中有1例会发生粒细胞缺乏症。应指导患者一旦发烧立即就医。
